Sonnet BioTherapeutics Holdings (SONN) said Monday its phase 1 trial of SON-1010 demonstrated a partial response and disease stabilization in adult patients with advanced solid tumors.
One patient in the highest-dose cohort experienced a 45% tumor reduction per RECIST criteria, while 48% of evaluable patients maintained stability at four months, the company said.
No dose-limiting toxicities or related serious adverse events have been reported, with most adverse events being mild and transient, Sonnet said.
Shares of the company surged nearly 116% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。